10-Q: Ispire Q3 2025: Revenue Drops, Net Loss Narrows Amid Cost Cuts

Ispire Technology Inc. reported a 22.8% revenue decrease to $30.35 million in Q3 2025, but significantly narrowed its net loss to $3.26 million from $5.60 million year-over-year, driven by substantial operating expense reductions.

Summary

• Revenue decreased by $8.99 million (22.8%) to $30.35 million for the three months ended September 30, 2025, compared to $39.34 million for the three months ended September 30, 2024.
• Net loss significantly decreased by $2.34 million (41.8%) to $3.26 million, or $(0.06) per share, for the three months ended September 30, 2025, compared to $5.60 million, or $(0.10) per share, for the three months ended September 30, 2024.
• Gross profit decreased by $2.53 million (32.9%) to $5.15 million, with gross margin declining from 19.5% to 17.0%.
• Operating expenses decreased by $5.10 million (39.4%) to $7.84 million, primarily due to reduced sales and marketing expenses ($1.43 million decrease) and general and administrative expenses ($2.33 million decrease).
• Credit loss expenses decreased by $1.34 million (43.1%) to $1.76 million.
• Working capital increased significantly by $8.95 million (2,431.3%) from $0.37 million at June 30, 2025, to $9.32 million at September 30, 2025.
• Cash and restricted cash decreased by $1.64 million to $22.71 million at September 30, 2025, from $24.35 million at June 30, 2025.
• The company identified material weaknesses in disclosure controls and internal control over financial reporting as of September 30, 2025.

Sentiment

Score: 4

Explanation: While the company demonstrated strong cost control leading to a reduced net loss and improved working capital, the significant decline in revenue and gross margin is a major concern. The heavy reliance on related-party transactions, coupled with identified material weaknesses in internal controls, introduces substantial governance and operational risks. The regulatory environment for vaping and cannabis products remains highly uncertain. The positive financial improvements are largely driven by cost-cutting rather than revenue growth.

Positives

• Net loss decreased significantly by 41.8% year-over-year, from $5.60 million to $3.26 million.
• Operating expenses were substantially reduced by 39.4%, from $12.94 million to $7.84 million.
• Sales and marketing expenses decreased by 47.7%, primarily due to lower stock-based compensation and travel expenses.
• General and administrative expenses decreased by 34.0%, mainly due to reduced payroll (headcount decrease in North America) and miscellaneous administrative expenses.
• Credit loss expenses decreased by 43.1%, attributed to improved customer payment collections.
• Working capital improved dramatically, increasing from $0.37 million to $9.32 million.
• Management believes current cash and cash flows, along with prior equity offerings and borrowing, will be sufficient for working capital needs for the next 12 months.

Negatives

• Revenue decreased by 22.8% to $30.35 million, driven by declines across all major regions (U.S., South Africa, Asia Pacific, Europe).
• Gross profit decreased by 32.9% to $5.15 million, and gross margin declined from 19.5% to 17.0% due to changes in product mix (less higher-margin products).
• The company continues to report a net loss of $3.26 million.
• Significant customer concentration, with two major customers (E and F) accounting for 16% and 15% of total accounts receivable, respectively, as of September 30, 2025.
• High supplier concentration, with Major Supplier D (Shenzhen Yi Jia, a related party) accounting for 92% of total purchases for Q3 2025.
• Cash and restricted cash decreased by $1.64 million during the quarter.
• The company has material weaknesses in disclosure controls and internal control over financial reporting.

Risks

• Government Regulations: E-cigarette and cannabis product regulations vary globally, with potential for new stringent laws, bans, or non-compliance issues.
• FDA PMTA Process: The FDA may reject the company's PMTA application for its ENDS product, preventing U.S. sales.
• PACT Act: Amendments extend the PACT Act to all vaping products, placing significant burdens on U.S. sellers, potentially making profitable operation difficult.
• Cannabis Federal Illegality: Cannabis and its derivatives (over 0.3% delta-9 THC) remain Schedule I controlled substances under U.S. federal law, prohibiting manufacture and distribution, and potentially deeming vaping products as drug paraphernalia.
• European TPD: Regulations on packaging, labeling, ingredients, and advertising for e-cigarettes in the EU. Sale of cannabis vaping products is illegal in the EU and UK.
• Customer Concentration: Reliance on a few major customers for a significant portion of accounts receivable.
• Supplier Concentration: Heavy reliance on a single related party supplier (Shenzhen Yi Jia) for the majority of vaping product purchases.
• Credit Risk: Potential negative impact from customers' failure to pay accounts receivable due to adverse economic conditions, ineffective collection efforts, or disputes.
• Liquidity Risk: While current cash is deemed sufficient for 12 months, adverse operating environments or accelerated growth could require additional financing, potentially leading to dilution.
• Internal Control Weaknesses: Lack of controls for evaluating significant estimates (inventory, credit loss reserves), insufficient personnel with U.S. GAAP knowledge, and lack of IT general controls regarding cybersecurity, logical access, and service organization management.
• Volatility of Operating Results and Stock Price: General risk factor mentioned in forward-looking statements.

Future Outlook

Management believes current cash and cash flows from operations, combined with net proceeds from prior equity offerings and borrowing, will be sufficient to meet working capital needs for the next 12 months. However, additional financing may be required if the operating environment is adverse, unanticipated capital expenditures arise, or growth is accelerated, which could lead to substantial dilution for stockholders. The company continues to develop its sales network for cannabis vaping products across Europe, South America, and other regions in preparation for future legalization.

Management Comments

• "We are committed to delivering superior products that challenge industry norms, with the goal of delivering an unmatched customer and adult consumer experience."
• "Risk reduction is central to our mission, and we aim to improve the lives of our consumers through cutting-edge research and development."
• "Our technology platforms look to reduce youth access to vaping products, which in turn, will facilitate our ability to provide adult consumers with the products they desire."
• "We work closely with our various global distribution partners to help ensure our nicotine products comply with local regulations."
• "As of the date of this Quarterly Report, we believe that our current cash and cash flows provided by operating activities, and the net proceeds from our equity offerings and borrowing will be sufficient to meet our working capital needs in the next 12 months."

Industry Context

The vaping industry is subject to diverse and evolving global regulations, with a particular focus on e-cigarettes and underage sales. The cannabis vaping market faces significant legal hurdles, especially in the U.S. where federal law still prohibits it, and in regions like the EU/UK where it remains illegal. The company is expanding its international presence for nicotine products and developing its cannabis sales network in anticipation of future legalization, indicating a strategy to navigate these complex regulatory landscapes and capitalize on emerging markets. The company's focus on ODM for cannabis products allows it to avoid direct handling of the cannabis plant, mitigating some specific regulatory and taxation burdens.

Corporate Governance

Legal Proceedings

• The company is not a party to, nor aware of, any legal or regulatory proceedings, investigations, or claims likely to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• The Company's Co-Chief Executive Officer and Chairman, Tuanfang Liu, and his wife, Jiangyan Zhu, are directors of both Ispire Technology Inc. and Aspire Global, and beneficially own 58.0% and 4.4% of Ispire, respectively.
• The majority of the Company's tobacco and cannabis vaping products were purchased from Shenzhen Yi Jia, a Chinese company 95% owned by Tuanfang Liu and 5% by his cousin.
• Accounts payable to Shenzhen Yi Jia was $47,442,029 as of September 30, 2025.
• An amount due to Shenzhen Yi Jia of $29,000,000 was reclassified from current accounts payable to non-current as Shenzhen Yi Jia agreed not to seek repayment for twelve months starting November 1, 2025; this balance is non-interest bearing and unsecured.
• The Company has a 40% membership interest in IKE Tech LLC, a joint venture, and had accounts receivable of $56,995 due from IKE as of September 30, 2025.
• The Company recorded $10,132 in other income from IKE for administrative fees.
• Ispire entered into an exclusive supply agreement with Berify (a JV partner), obligating Ispire to purchase all Bluetooth-enabled integrated circuits for vape devices sold to IKE at cost plus a 20% mark-up.
• IKE entered into an exclusive supply agreement with Ispire, obligating IKE to purchase all products sold by IKE in the nicotine field at cost plus a 5% mark-up.

Stakeholder Impact

• Shareholders: Potential for dilution if additional equity financing is pursued; stock price volatility due to financial performance and regulatory risks; share repurchase program could provide some support.
• Employees: Decrease in headcount in North America contributed to reduced general and administrative expenses.
• Customers: Decreased sales across all regions indicate potential challenges in market demand or competitive pressures; payment terms and credit loss management are critical.
• Suppliers: High concentration on a single related-party supplier (Shenzhen Yi Jia) creates dependency and potential for conflicts of interest.
• Creditors: The reclassification of $29 million from current to non-current related party payables improves current liquidity but highlights significant related-party debt.

Next Steps

• Continue to develop and implement internal controls over financial reporting to address identified material weaknesses.
• Construction-in-progress for the Malaysia office and production plant is expected to be put into use during fiscal year 2026.
• Continue to develop sales network for cannabis vaping products across Europe, South America, and other regions in preparation for legalization.
• FDA review of the submitted PMTA for one ENDS product is pending.

Key Dates

Recommendation

While the company demonstrated strong cost control leading to a reduced net loss and improved working capital, the significant decline in revenue and gross margin is a major concern. The heavy reliance on related-party transactions, coupled with identified material weaknesses in internal controls, introduces substantial governance and operational risks. The regulatory environment for vaping and cannabis products remains highly uncertain. An investor should hold to observe if the cost-cutting measures can be sustained while revenue growth stabilizes or improves, and if the internal control deficiencies are effectively remediated. The long-term outlook is clouded by regulatory hurdles and market competition.

Keywords

Vaping, e-cigarettes, cannabis, hardware, ODM, SEC filing, quarterly report, financial results, regulatory risk, internal controls, Ispire Technology